Exicure Inc Trading Halted Due to Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Exicure Inc trading halted, volatility trading pause
Get Free Real-Time Notifications for Any Stock
Monitor tickers like XCUR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on XCUR
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Continue Reading
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
Continue Reading